The CardioGenomic Testing Alliance (CGTA) aims to raise awareness and utilization of genomic testing in cardiology. The alliance seeks to educate health care providers and other stakeholders about the value of such testing to assure adherence to existing guidelines from professional medical societies, to inform medical management and cascade testing, and to improve clinical outcomes.
The CardioGenomic Testing Alliance (CGTA) is a collaborative alliance comprised of leading genomics companies and laboratories. The alliance was launched in March 2022 with the primary goal of educating heath care providers and other stakeholders about the value of genomic testing in cardiology. Despite evolving technology and scientific guidelines from leading cardiology professional societies, utilization and awareness of genomic testing remains low among cardiovascular practitioners.
This alliance seeks to unite genomics companies, laboratories, digital health companies, advocacy groups, and key leaders in cardiology to improve clinical outcomes through education and awareness of genomic testing in cardiology.